Libivirumab
Libivirumab (17.1.41) is a human anti-HBV monoclonal antibody. Libivirumab shows neutralization activity with IC50s of 35, 130 ng/mL for HBsAg, HBeAg, respectively[1].
Product Specifications
CAS Number
[569658-79-3]
Product Name Alternative
17.1.41
UNSPSC
12352203
Target
HBV
Type
Inhibitory Antibodies
Related Pathways
Anti-infection
Applications
COVID-19-anti-virus
Field of Research
Infection
Assay Protocol
https://www.medchemexpress.com/libivirumab.html
Purity
98.27
Solubility
10 mM in DMSO
Smiles
[Libivirumab]
Molecular Weight
(149.04 kDa)
References & Citations
[1]Wang Q, et al. A Combination of Human Broadly Neutralizing Antibodies against Hepatitis B Virus HBsAg with Distinct Epitopes Suppresses Escape Mutations. Cell Host Microbe. 2020 Aug 12;28 (2) :335-349.e6.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Available Sizes
More Discoveries
Explore Other Products
Browse additional items from our catalog
MBS626342-01 0.1 mg
SARS, Spike Protein (Severe Acute Respiratory Syndrome, SARS-CoV, SARS Associated Coronavirus)
Sign In for Pricing
View Details 
MBS626342-02 5x 0.1 mg
SARS, Spike Protein (Severe Acute Respiratory Syndrome, SARS-CoV, SARS Associated Coronavirus)
Sign In for Pricing
View Details MBS1018063-01 0.02 mg (E-Coli)
Recombinant Chloroherpeton thalassium Dihydrodipicolinate synthase (dapA)
Sign In for Pricing
View Details